Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis

Wednesday, June 1, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

- Plenary presentation of Phase III study examining benefit of extended adjuvant treatment with Gleevec® for three years vs. one year for patients with KIT+ GIST

Novartis Media Relations

Media only:

Investors only:

Gloria Vanderham

Richard Jarvis

Novartis Oncology

Novartis Corporation

P: +1 862 778 4268

P: +1 212 830 2433

Dana Kahn Cooper

[email protected]

P: +1 732 817 1800

F: +1 732 817 1834



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store